Conclusions: Rituximab is a safe and effective alternative to cyclophosphamide in the primary therapy of skin and lung manifestations of scleroderma.

Disclose of Interest: None declared


**THU0407**

EVALUATION OF SOLUBLE AND MEMBRANE HLA-G IN PATIENTS WITH SYSTEMIC SCLEROSIS AND ROLE OF THESE MOLECULES IN THE PATHOGENESIS OF THE DISEASE

G. Murdaca, P. contini, S. Negrini, M. Borro, F. Puppo. **Internal Medicine, University of Genova, Genova, Italy**

**Background:** Systemic sclerosis (SSc) is a complex disease characterised by immune abnormalities, vascular damage and fibrosis. Human leukocyte antigen-G (HLA-G) is a non-classic class I major histocompatibility complex (MHC) molecule expressed on different cell lineages in both physiological and pathological conditions and detectable in soluble forms (sHLA-G and HLA-G5 shed and secreted isoform, respectively). Several immunomodulatory functions have been attributed to both membrane-bound and soluble HLA-G molecules. HLA-G is expressed on extravillous cytotrofoblast, in placenta but also in a few normal tissues, solid tumours, transplanted organs and virally infected cells. Soluble form (sHLA-G) derives from shedding of cleaved surface isoforms (sHLA-G1) or secretion of soluble isoforms (HLA-G5). Immunosuppressive functions have been attributed to both membrane HLA-G (mHLA-G) and sHLA-G.

**Objectives:** The aims of the present study were: 1) to determine the serum levels of sHLA-G molecules in a cohort of SSc patients with the limited or diffuse form of the disease; 2) to correlate sHLA-G levels with TGF-β; 3) to evaluate the expression of HLA-G in peripheral blood mononuclear cells (PBMC).

**Methods:** Thirtyfive patients (28 females/7 males, age 40–89 years) with diffuse SSc (dsSSc, n. 12) or limited SSc (lsSSc, n. 23) and 40 healthy sex and age matched controls were enrolled. Plasma sHLA-G, sHLA-G1 and HLA-G5 levels were determined by immunoenzymatic assays. mHLA-G expression in peripheral blood mononuclear cells (PBMC) was evaluated by flow cytometry.

**Results:** The plasma levels of sHLA-G were higher in SSc patients (444.27 ± 304.84 U/ml) compared to controls (16.74 ± 20.58 U/ml) (p<0.0001). The plasma levels of TGF-β were higher in SSc patients (11099 ± 6081 pg/ml; p=0.003) and a significant correlation was found and the plasma levels of total sHLA-G (r: 0.65; p<0.01), sHLA-G1 (r: 0.47; p=0.02) and HLA-G5 (r: 0.60; p=0.003) and the plasma levels of total sHLA-G (r: 0.65; p<0.01), sHLA-G1 (r: 0.47; p=0.02) and HLA-G5 (r: 0.60; p=0.003) were determined by immunoenzymatic assays, mHLA-G expression in peripheral blood mononuclear cells (PBMC) was evaluated by flow cytometry.

**Conclusions:** These data indicate that in SSc secretion and/or shedding of sHLA-G and mHLA-G are clearly elevated and involved in immune dysregulation.

**REFERENCES:**


**Acknowledgements:** This work was supported by “Gruppo Italiano Lotta alla Scleroderma” (GILS). The sponsor had no role in study design, in the collection, analysis and interpretation of data, in the writing of the report, and in the decision to submit the article for publication.

**Disclosure of Interest:** None declared

**DOI:** 10.1136/annrheumdis-2018-eular.3241

**THU0408**

CHARACTERISTICS OF MILD TO MODERATE LUNG DISEASE IN SYSTEMIC SCLEROSIS AND IMPACT OF SURVIVAL: DATA FROM THE POPULATION-BASED, NATIONWIDE NORWEGIAN COHORT

H. Fretheim1, M. Seip2, A.-K. Halse3, H. Bitter4, M. Wallenius5, M. Aalokken1, T. Garen1, Ø. Midtvedt1, Ø. Molberg1, A.-M. Hoffmann-Vold1. 1Oslo University Hospital, Oslo; 2University Hospital of North Norway, Tromsø; 3Haukeland University Hospital, Bergen; 4Hospital of Southern Norway, Kristiansand; 5St. Olav’s University Hospital, Trondheim, Norway

**Background:** In systemic sclerosis (SSc) it is well-documented that severe interstitial lung disease (ILD) defined as an extent of lung fibrosis >20% on high resolution computed tomography (HRCT) is strongly associated with male gender, anti-topoisomerase antibody (ATA), diffuse cutaneous (dc) form of disease and decreased survival. Much less is, however, known about the disease characteristics and impact of less lung involvement. A possible explanation might be the selected nature of many hitherto investigated SSc cohorts. In an era with novel treatment options, and multiple ongoing clinical trials, it is important to gain natural history knowledge on the whole spectrum of lung involvement in systemic sclerosis.

**Objectives:** Characterise the SSc patients with mild to moderate ILD, defined as 1–10% extent of lung fibrosis on HRCT in the population based nationwide Norwegian SSc cohort and assess the impact of this ILD form on survival.

**Methods:** The Norwegian, nationwide SSc (Nor-SSc) study cohort included all adult SSc patients who were resident in Norway between 01.01.2000–01.01.2013 and met the classification criteria for SSc. Detailed electronic patient journal review was performed in all patients to assess demographic, clinical and ILD features at baseline. Pulmonary function tests (PFTs) and lung HRCT images were analysed and the extent of lung fibrosis was expressed as percentage of total lung volumes. We defined mild-moderate ILD as 1–10% fibrosis on HRCT and severe disease as >20% fibrosis. Ground glass opacities, bronchiectasis and honeycombng were registered if present. Vital status and causes of deaths were available in all patients at study end (January 2018). Descriptive statistics and regression analysis were applied.

**Results:** The Nor-SSc cohort included 815 patients. Baseline lung HRCT images were available in 416 patients (51%), whereof 226 (54.3%) had signs compatible with ILD. Mild to moderate ILD, defined as 1–10% lung fibrosis were present in 149 (65.9%), while 48 (21.2%) had extensive lung fibrosis defined as >20%. Observed survival in mild-moderate ILD were 55.2 years at SSc onset and characterized by female gender (81.9%) and limited cutaneous SSc (70.5%). Their antibody profile was dominated by anti-centromere Ab (ACA) in 48.3%, followed by anti-ribonucleoprotein III, ATA, and anti-RNP, in 14.1%, 13.4% and 5.4%, respectively. The mean modified Rodnan skin score (mRSS) was 9.3 (9.3%), baseline FVC was 93.4% and DLCO 66.5%. Univariable associations of clinical characteristics and mild-moderate ILD are shown in figure 1. After a mean observation time of 8.2 years, 49 (32.9%) of patients with mild-moderate ILD had died. The 5- and 10 year survival was 76% and 62% compared to 83% and 76% in patients with no ILD (p=0.03). In univariable cox regression analyses, mild-moderate ILD was associated with mortality (HR 1.6, 95% CI 1.03–2.40, p=0.034).

### Figure 1

<table>
<thead>
<tr>
<th></th>
<th>DCO</th>
<th>FVC</th>
<th>mRSS</th>
<th>ACA</th>
<th>ARA</th>
<th>ATA</th>
<th>dcSSc</th>
<th>Male sex</th>
<th>Age at onset</th>
</tr>
</thead>
<tbody>
<tr>
<td>OR (95% CI)</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
</tbody>
</table>

**Conclusions:** In this population based, nationwide study, mild-moderate ILD was frequent and had a considerably impact on survival in SSc patients.

**Disclosure of Interest:** None declared

**DOI:** 10.1136/annrheumdis-2018-eular.7121